TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20141705
Drug: TAU augmented
Normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU augmented with brief group cognitive therapy (CT)
Study: 8688398
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose ritodrine infusion
Study: 8688398
Drug: Conventional schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional schedule of increasing doses of ritodrine
Study: 373072
Drug: Atropine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.5 mg)
Study: 30761568
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal therapy (PT)
Study: 27390130
Drug: IV→150 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV→150 mg secukinumab
Study: 27390130
Drug: IV→75 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV→75 mg secukinumab
Study: 18605891
Drug: Conventional surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional surgical therapy
Study: 10505301
Drug: Cerivastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin treatment
Study: 2012456
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of aspirin with 64 mg of caffeine
Study: 2012456
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of aspirin
Study: 23497560
Drug: Shape Up-LD
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shape Up-LD intervention (12 weekly sessions including healthy eating messages, advice on physical activity, and behaviour change techniques)
Study: 21803749
Drug: Stopping NSAIDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopping NSAIDs (for a minimum of 5 drug half-lives)
Study: 17313721
Drug: Chocolate milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chocolate milk (500 ml, 900 kJ)
Study: 17313721
Drug: Cola (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cola (500 ml, 900 kJ)
Study: 15369934
Drug: Pre-emptive antiemetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-emptive antiemetic therapy
Study: 15369934
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no pre-emptive therapy)
Study: 11394392
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of enamel matrix proteins (EMP), bovine porous bone mineral (BPBM), and a bioabsorbable membrane for guided tissue regeneration (GTR)
Study: 2500361
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 4 x 0.1 mg.day‐1
Study: 2500361
Drug: Inhaled cromoglycate
Normalized name: cromoglycate
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled cromoglycate 4 x 2 mg.day‐1
Study: 23646465
Drug: Live Combined
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live Combined Bifidobacterium and Lactobacillus Tablets (Control)
Study: 17137211
Drug: Telmisartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (40 mg once daily for 24 weeks)
Study: 17137211
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg once daily for 24 weeks)
Study: 11003445
Drug: Allergen-specific immunotherapy
Normalized name: Pacific halibut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen-specific immunotherapy with birch pollen extract
Study: 11003445
Drug: Allergen-specific immunotherapy
Normalized name: Pacific halibut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen-specific immunotherapy with grass pollen extract
Study: 8622574
Drug: Cortisol 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol 10 mg orally
Study: 1315685
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg repirinast
Study: 1315685
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg repirinast
Study: 1315685
Drug: 450 mg
Normalized name: aspirin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg repirinast
Study: 3908675
Drug: fenoprofen calcium,
Normalized name: fenoprofen calcium, dihydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenoprofen calcium, 200 mg
Study: 3908675
Drug: fenoprofen calcium,
Normalized name: fenoprofen calcium, dihydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenoprofen calcium, 400 mg
Study: 3908675
Drug: aspirin, 650
Normalized name: Aspirin, 650 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin, 650 mg
Study: 28734107
Drug: XRNTX 380
Approvals — FDA: no, EMA: no, PMDA: no
Description: XRNTX 380 mg administered by gluteal injection at 4-week intervals (n=50)
Study: 28734107
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo administered by gluteal injection at 4-week intervals (n=50)
Study: 28734107
Drug: XRNTX 380
Approvals — FDA: no, EMA: no, PMDA: no
Description: XRNTX 380 mg
Study: 26569149
Drug: Rotigotine (1‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine (1‐3 mg/24 h)
Study: 24764585
Drug: Black raspberries
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black raspberries (BRBs) - daily for 9 months, including BRB powder orally and two BRB suppositories at bedtime
Study: 24764585
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo plus BRB suppositories
Study: 24764585
Drug: Black raspberries
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black raspberries (BRBs) - daily for 9 months
Study: 20569707
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of baseline TnT and ST-segment resolution (STRes)
Study: 15894560
Drug: Propofol-Lipuro (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol-Lipuro (3 mg/kg)
Study: 15894560
Drug: Diprivan with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diprivan with added lidocaine (0.3 mg/kg)
Study: 9809085
Drug: Granisetron 40
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron 40 micrograms.kg‐1 plus dexamethasone 8 mg i.v.
Study: 665535
Drug: Placebo (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (after 3 days of therapy and again after 30 days)
Study: 12873937
Drug: Propofol total
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol total intravenous anesthesia
Study: 24754350
Drug: BoNT/A treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT/A treatment (230 or 460 U onabotulinumtoxinA)
Study: 22762347
Drug: 4 mm
Normalized name: potassium 8.4 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mm × 32 G pen needle
Study: 20740615
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide (CYC) for 1 year
Study: 11976244
Drug: Eradication treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication treatment (omeprazole 20 mg, metronidazole 500 mg, and clarithromycin 250 mg for 7 days)
Study: 11976244
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (omeprazole 20 mg, placebo metronidazole, and placebo clarithromycin for 7 days)
Study: 1696577
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antithrombin III and heparin
Study: 7016248
Drug: Podophyllin treatment
Normalized name: podophyllin
DrugBank: Podophyllin (DB09094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Podophyllin treatment (10% and 25%)
Study: 31619437
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg amoxicillin three times daily for three months
Study: 29037637
Drug: Yoga program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga program (30 min per day, twice a week for 12 weeks)
Study: 25646368
Drug: Debio0932 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debio0932 at a dose of 1000 mg daily
Study: 25646368
Drug: Debio0932 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debio0932 at doses up to 1600 mg
Study: 23061323
Drug: Ongoing counseling
Normalized name: Ongo-Fin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing counseling and methadone maintenance therapy
Study: 15934353
Drug: Fiber 7
Normalized name: pedi nutrit.,soy,iron,lf/fiber 7 gram-237 kcal/52 gram ORAL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber 7 supplement (7 g per meal twice a day)
Study: 12447093
Drug: Lidocaine with
Normalized name: Lidocaine with Tegaderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine with steroid
Study: 2189591
Drug: Etoposide (VP‐16)
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide (VP‐16) 100, 150, or 225 mg/m2 infused over 2 h into the pleural space after drainage of pleural fluid
Study: 2189591
Drug: Etoposide (VP‐16)
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide (VP‐16) 225 mg/m2
Study: 27984230
Drug: Wound Infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wound Infiltration (15 mL of bupivacaine 0.25% in each side of the surgical wound, total 30 mL)
Study: 27984230
Drug: Transversus Abdominis
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transversus Abdominis Plane (TAP) Block (20 mL of bupivacaine 0.25% bilaterally, total 40 mL)
Study: 26216675
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) 10 mg, bid for 3 months
Study: 26216675
Drug: Indomethacin 25
Normalized name: indomethacin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 25 mg, bid for 3 months
Study: 20801436
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone gel (TTG) pretreatment, 12.5 mg applied daily for 21 days before COS
Study: 19373657
Drug: Thalidomide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (200 mg/d, with dose escalation up to 1000 mg/d over 60 days)
Study: 17302070
Drug: Pifukang lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pifukang lotion
Study: 16476934
Drug: Tetrabenazine (TBZ),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrabenazine (TBZ), maximum dosage of 100 mg/day for 12 weeks
Study: 12627850
Drug: G‐CSF (lenograstim)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (lenograstim)
Study: 10784622
Drug: Cyclophosphamide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide plus G-CSF (regimen C)
Study: 10784622
Drug: Granulocyte-macrophage colony-stimulating
Normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte-macrophage colony-stimulating factor plus G-CSF (regimen G)
Study: 24254262
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate 400 mg bid plus amoxicillin 1 g bid plus clarithromycin 500 mg bid
Study: 24254262
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg bid plus amoxicillin 1 g bid plus clarithromycin 500 mg bid
Study: 17225018
Drug: Fucicort Lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fucicort Lipid cream
Study: 17225018
Drug: Fucicort cream
Normalized name: betamethasone Topical Cream [Uticort]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fucicort cream
Study: 14717749
Drug: Ventilation scintigraphy
Normalized name: VENTILATOR FILTER,THERMOFLO #6000S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventilation scintigraphy after inhalation of technegas
Study: 9222077
Drug: Maalox (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maalox (30 mL) with trovafloxacin (100 mg)
Study: 9222077
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with trovafloxacin (100 mg)
Study: 9222077
Drug: Maalox (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maalox (30 mL) 2 h before trovafloxacin (100 mg)
Study: 9222077
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg) with trovafloxacin (100 mg)
Study: 24029165
Drug: Nicotine e‐cigarettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine e‐cigarettes (16 mg)
Study: 24029165
Drug: Nicotine patches
Normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patches (21 mg, one daily)
Study: 24029165
Drug: Nicotine e‐cigarettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine e‐cigarettes vs patches
Study: 17058847
Drug: Combined Salmeterol/Fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Salmeterol/Fluticasone 50/250 mg for 6 weeks
Study: 12752647
Drug: Glyde File
Normalized name: Chamois Glide
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyde File Prep with 0.5 mL of 1% NaOCl irrigation after each file size and an additional final irrigation of 10 mL 1% NaOCl
Study: 12752647
Drug: 17% EDTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17% EDTA with 0.5 mL of 1% NaOCl irrigation after each file size and an additional final irrigation of 10 mL 17% EDTA
Study: 12752647
Drug: 1% NaOCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% NaOCl with 0.5 mL of 1% NaOCl irrigation after each file size and an additional final irrigation of 10 mL 1% NaOCl
Study: 3912977
Drug: Acyclovir 10
Normalized name: acyclovir 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 10 mg/kg, 8‐hourly for 10 days
Study: 24629989
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg/d for 30 days (group 1)
Study: 24629989
Drug: Clopidogrel 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 150 mg/d for 30 days (group 2)
Study: 24629989
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg/d (group 1)
Study: 24629989
Drug: Clopidogrel 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 150 mg/d (group 2)
Study: 20683333
Drug: Propofol-remifentanil total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol-remifentanil total intravenous anaesthesia (Group TIVA)
Study: 19167593
Drug: NXY-059 (8-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: NXY-059 (8-hour IV infusion with a 1-hour loading dose at 3x maintenance rate)
Study: 8242282
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 2.5 l of a 2.5% glucose/0.45% NaCl solution
Study: 8242282
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion of 100 ml 0.9% NaCl
Study: 3741714
Drug: Pindolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (5 mg twice daily)
Study: 30465360
Drug: Sildenafil alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil alone (2 mg/kg per dose, three times a day)
Study: 30465360
Drug: Sildenafil plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil plus Bosentan (Sildenafil: 2 mg/kg per dose, three times a day; Bosentan: 1 mg/kg per dose, twice a day)
Study: 24923683
Drug: Colloid-based therapy
Normalized name: colloidal oatmeal Topical Lotion [Theraplex Eczema Therapy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid-based therapy
Study: 24923683
Drug: Crystalloid-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid-based therapy
Study: 22070352
Drug: Daily consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily consumption of apple (1-128 g), doubling every 2-3 weeks
Study: 18194591
Drug: Carisoprodol 250-mg
Normalized name: carisoprodol 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carisoprodol 250-mg tablets
Study: 15932830
Drug: IV fluid
Normalized name: IV fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV fluid bolus of 1,000 mL
Study: 15932830
Drug: IV fluid
Normalized name: IV fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV fluid bolus of 500 mL
Study: 15932830
Drug: Oxygen administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen administration at 10 L/min via nonrebreather face mask
Study: 15932830
Drug: Oxygen administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen administration for fetuses with FSpO(2) < 40%
Study: 15932830
Drug: Oxygen administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen administration for fetuses with FSpO(2) ≥ 40%
Study: 12109341
Drug: Dietary supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplements (androstenedione, beta-carotene, CoQ10, garlic, soy, vitamin C and E)
Study: 11107583
Drug: Measurement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measurement of antiacetylcholine receptor antibodies
Study: 11107583
Drug: Diagnostic value
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnostic value of acetylcholine receptor antibodies measurement
Study: 8750768
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of glipizide given 30 min before glucose ingestion
Study: 8750768
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of glipizide ingested at 120 min during euglycemic insulin clamps
Study: 7362734
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg nomifensine
Study: 3265525
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg amitriptyline
Study: 6437877
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg Epostane
Study: 6437877
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Epostane
Study: 29471206
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (n = 204)
Study: 29471206
Drug: No music
Approvals — FDA: no, EMA: no, PMDA: no
Description: No music therapy (n = 205)
Study: 15672030
Drug: Plasma volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma volume expansion (250 mL hydroxyethyl starch 6% twice daily in 4 hours, and NaCl 0.9% between doses)
Study: 15672030
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (NaCl 0.9% when necessary with medication)
Study: 14683655
Drug: Whole virus
Normalized name: rabies, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole virus vaccine (7.5 microg, 15 microg, or 30 microg)
Study: 14683655
Drug: Subunit vaccine
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subunit vaccine (7.5 microg, 15 microg, or 30 microg)
Study: 14683655
Drug: Whole virus
Normalized name: rabies, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole virus vaccine (one dose)
Study: 14683655
Drug: Subunit vaccine
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subunit vaccine (one dose)
Study: 14683655
Drug: Whole virus
Normalized name: rabies, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole virus and subunit vaccines (two doses)
Study: 31840323
Drug: Nutrition orientation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition orientation and a normoproteic, normocaloric nutrition supplement (group 2)
Study: 31840323
Drug: Nutrition orientation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition orientation and the nutritional supplement with TGF‐Î²2 (group 3)
Study: 22318328
Drug: Re-irradiation with
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-irradiation with a total dose of 50 Gy (25 fractions over 5 weeks) combined with 900 mg/m²/day capecitabine
Study: 18302607
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy for insomnia (CBT-I) including stimulus control instructions, sleep restriction therapy, and sleep education and hygiene.
Study: 15943846
Drug: Famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 20 mg/day for 4 weeks
Study: 15943846
Drug: Mosapride citrate
Normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride citrate 15 mg/day for 4 weeks
Study: 15943846
Drug: Amitriptyline 30
Normalized name: amitriptyline 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 30 mg/day for 4 weeks (second-step therapy)
Study: 15943846
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (control for second-step therapy)
Study: 14598618
Drug: ketamine (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketamine (0.7 mg/kg)
Study: 10807895
Drug: Hydrothermally processed
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrothermally processed cereals (active treatment)
Study: 10807895
Drug: Ordinary cereals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary cereals (placebo treatment)
Study: 21914148
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam 0.015 mg/kg (Group S)
Study: 16857659
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg estradiol valerate continuously with an addition of 10 mg medroxyprogesterone acetate (MPA) during the last 12 days of the 28‐day cycle
Study: 9015114
Drug: Bovine and
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bovine and rhesus rotavirus vaccines (meta-analysis)
Study: 9015114
Drug: Bovine and
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bovine and rhesus rotavirus vaccines
Study: 6829497
Drug: Continuous vindesine
Normalized name: vindesine
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous vindesine (1.2 mg/m2, 5-day infusion, every 3 weeks)
Study: 6829497
Drug: Continuous vinblastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous vinblastine (1.5 mg/m2/day, every 3 weeks)
Study: 15598790
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of alcohol daily (two drinks)